

## REMARKS


The Examiner has restricted the above-captioned application under 35 U.S.C. § 121 to one of the following two claim groups:

Group I: claims 1-14, 16, and 17, drawn to methods and products for inducing proliferation of a neural stem cell.

Group II: claims 15 and 18, drawn to a therapeutic agent and method of treating cerebral infarction comprising GM-CSF.

In light of the Examiner's restriction requirement, Applicants hereby elect the invention of Group I, encompassing claims 1-14, 16, and 17, for prosecution in the above-captioned application. Applicants reserve the right to prosecute the remaining Group in a continuing or divisional application. The elected claims are believed to be in condition for allowance. Passage of the above-captioned application to issuance is requested.

Respectfully submitted,



---

Bradford G. Addison  
Registration No. 41,486  
Attorney for Applicants

BGA:  
Indianapolis, Indiana 46204  
317-231-7253